South African Rheumatism and Arthritis Association 2024 guidelines for the management of peripheral spondyloarthritis
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i10.3470Keywords:
peripheral spondyloarthritis, south africa, guidelinesAbstract
Peripheral spondyloarthritis (SpA) includes psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated arthritis, reactive arthritis and undifferentiated peripheral SpA. These South African guidelines offer information on diagnosis, assessment and therapy of peripheral SpA. Emphasis is placed on a multidisciplinary team, and a treat-to-target strategy with escalation of therapy if the target of minimal or very low disease activity is achieved. Screening for and treatment of comorbidities are paramount.
References
1. Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: Recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis 2018;10(5-6):129-139. https://doi. org/10.1177/1759720X18773726
2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78. https://doi. org/10.1016/0049-0172(73)90035-8
3. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005;141(12):1537-1541. https://doi.org/10.1001/archderm.141.12.1537
4. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Dermato-Venereologica 1981;61(4):344-346.
5. Ferrándiz C, Bordas, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Euro Acad Dermatol Venereol 2001;15(1):20-23.
6. Zabotti A, de Lucia O, Sakellariou G, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: A systematic literature review and meta-analysis. Rheumatol Ther 2021;8(4):1519-1534. https://doi.org/10.1007/s40744-021-00378-w
7. Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria – a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39(1):154-156. https:// doi.org/10.3899/jrheum.110845
8. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060-1071. https://doi.org/10.3899/jrheum.11084510.1002/art.39573
9. Chandran V, Maharaj AB. Assessing disease activity in psoriasis and psoriatic arthritis: Impact on management and therapy. Expert Rev Clin Immunol 2016;12(5):573-582. https://doi.org/10.1586/17 44666X.2016.1146133
10. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Ann Rheumat Dis 2016;75(5):811-818. https://doi.org/10.1136/annrheumdis-2015-207507
11. Scarpa R, Pucino A. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Dermato-Venereologica 1989;69:69-71.
12. FeldmanS,KruegerG.Psoriasisassessmenttoolsinclinicaltrials.AnnRheumatDis2005;64(Suppl2):ii65- ii168. https://doi.org/10.1136/ard.2004.031237
13. Farber E, Nall L. Nail psoriasis. Cutis 1992;50(3):174-178.
14. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: Interrelationships between skin and joint
manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-305.
15. Williamson L, Dalbeth N, Dockerty J, Gee B, Weatherall R, Wordsworth B. Nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology 2004;43(6):790-
794. https://doi.org/10.1093/rheumatology/keh1981.
16. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49(2):206-212. https://doi.org/10.1067/S0190-9622(03)00910-1
17. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34(1):123-129.
18. Hanly JG, Russell ML, Gladman D. Psoriatic spondyloarthropathy: A long term prospective study. Ann
Rheumat Dis 1988;47(5):386-393.
19. Scarpa R, Oriente P, Pucino A, et al. The clinical spectrum of psoriatic spondylitis. Rheumatology
1988;27(2):133-137. https://doi.org/10.1093/rheumatology/27.2.133
20. Helliwell P, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ
from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and
reactive arthritis? Ann Rheumat Dis 1998;57(3):135-140. https://doi.org/10.1136/ard.57.3.135
21. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool
for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32(9):1745-1750.
22. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opinion Rheumatol 2005;17(4):406-412. https://
doi.org/10.1097/01.bor.0000167752.93543.76
23. Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: A review of the literature. J Rheumatol 2018;45(1):6-13. https://doi.org/10.3899/jrheum.170449
24. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: Results from a single
outpatient center. II. Prognostic indicators for death. Arthritis Rheumatol 1998;41(6):1103-1110.
25. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Ann Rheumat Dis 2007;66(3):370-376. https://doi.org/10.1136/
ard.2006.056457
26. Sheehan NJ. The ramifications of HLA-B27. J Royal Soc Med 2004;97(1):10-14.
27. Panagiotopoulos A, Fragoulis GE. Comorbidities in psoriatic arthritis: A narrative review. Clin Ther
2023;45(2):177-189. https://doi.org/10.1016/j.clinthera.2023.01.006
28. Elmamoun M, Eraso M, Anderson M, et al. International league of associations for rheumatology
recommendations for the management of psoriatic arthritis in resource-poor settings. Clin Rheumatol
2020;39:1839-1850. https://doi.org/10.1007/s10067-020-04934-7
29. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis:
Evidence from a controlled study with nimesulide. Clin Experiment Rheumatol 2001;19(Suppl 22):S-17.
30. Brenner M, Molin S, Ruebsam K, Weisenseel P, Ruzicka T, Prinz J. Generalised pustular psoriasis induced by systemic glucocorticosteroids: Four cases and recommendations for treatment. Br J Dermatol
2009;161(4):964-966. https://doi.org/10.1111/j.1365-2133.2009.09348.x
31. Gregoire AR, DeRuyter BK, Stratman EJ. Psoriasis flares following systemic glucocorticoid exposure
in patients with a history of psoriasis. JAMA Dermatol 2021;157(2):198-201. https://doi.org/10.1001/
jamadermatol.2020.4219
32. Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010;49(7):1367-1373. https://doi.org/10.1093/rheumatology/keq102
33. Lindström U, di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheumat Dis 2021;80(11):1410-1418. https://doi.org/10.1136/annrheumdis-2021-220097
34. Diels J, Thilakarathne P, Schubert A, McElligott S. Comparing efficacy of guselkumab versus ustekinumab in moderate to severe psoriasis patients: An adjusted comparison based on Voyage 1&2 and Navigate Trials. Value Health 2017;20(9):A544-A545.
35. Papp KA, Yang M, Sundaram M, et al. Comparison of adalimumab and etanercept for the treatment of moderate to severe psoriasis: An indirect comparison using individual patient data from randomised trials. Value Health 2018;21(1):1-8. https://doi.org/10.1016/j.jval.2017.05.025
36. Thomas AS. Biologics for the treatment of noninfectious uveitis: Current concepts and emerging therapeutics. Curr Opinion Ophthalmol 2019;30(3):138-150. https://doi.org/10.1097/ ICU.0000000000000562
37. FragoulisGE,SiebertS.TheroleofIL-23andtheuseofIL-23inhibitorsinpsoriaticarthritis.Musculoskel Care 2022;20:S12-S21. https://doi.org/10.1002/msc.1694
38. Atzeni F, Siragusano C, Masala IF, Carriero A, Picerno V, D’Angelo S. IL-23 in axial spondyloarthritis and psoriatic arthritis: A good fit for biological treatment? Expert Opin Biolog Ther 2022;22(7):843-853. https://doi.org/10.1080/14712598.2022.2090834
39. KavanaughA,PuigL,GottliebAB,etal.Efficacyandsafetyofustekinumabinpsoriaticarthritispatients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheumat Dis 2016;75(11):1984-1988. https://doi.org/10.1136/annrheumdis-2015-209068
40. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: Primary results from a randomised, controlled phase III trial. Arthritis Rheumatol 2019;71(7):1112-1124. https://doi.org/10.1002/art.40851
41. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskel Med 2011;4:123-131. https://doi.org/10.1007/s12178-011-9085-8
42. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomised, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4(2):203-211. https://doi.org/10.1016/j.cgh.2005.12.002
43. Olivieri I, Cantini F, Castiglione F, et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmunity Rev 2014;13(8):822-830. https://doi.org/10.1016/j.autrev.2014.04.003
44. Cassinotti A, Batticciotto A, Parravicini M, et al. Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeut Adv Gastroenterol 2022;15:17562848221085889. Ther Adv Gastroenterol 2022;15:1-30. https://doi.org/10.1177/ 17562848221085889
45. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340(18):1398-1405.
46. Carbonnel F. Methotrexate: A drug of the future in ulcerative colitis? Curr Drug Targets 2011;12(10): 1413-1416. https://doi.org/10.2174/138945011796818252
47. SandbornWJ,HanauerSB,RutgeertsP,etal.AdalimumabformaintenancetreatmentofCrohn’sdisease: Results of the CLASSIC II trial. Gut 2007;56(9):1232-1239. https://doi.org/10.1136/gut.2006.106781
48. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive
arthritis. Ann Rheumat Dis 2003;62(7):655-658.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
